引用本文: | 评价者: 王宁霞, 文献合成者: 张一方. 循环肿瘤DNA中PIK3CA突变状态可预测Buparlisib联用氟维司群在部分应用芳香化酶抑制剂乳腺癌患者的疗效[J]. 循证医学, 2016, 16(3): 149-151. DOI: 10.12019/j.issn.1671-5144.2016.03.008 |
Citation: | Reviewer: WANG Ning-xia, Literature Co-worker: ZHANG Yi-fang. PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib (BUP) Plus Fulvestrant (FULV) in Breast Cancer Patient with Aromatase Inhibitors[J]. Journal of Evidence-Based Medicine, 2016, 16(3): 149-151. DOI: 10.12019/j.issn.1671-5144.2016.03.008 |